Table 1. Patient characteristics.
| Characteristic | Value (n=66) |
|---|---|
| Age, yr | 57 (34–80) |
| Sex | |
| Male | 44 (66.7) |
| Female | 22 (33.3) |
| Smoking history | |
| Ever smoker | 46 (69.1) |
| Never smoker | 20 (30.3) |
| Stage at EGFR TKI use | |
| IIIb | 2 (3.0) |
| IV | 64 (97.0) |
| ECOG PS at TKI treatment | |
| 0–1 | 41 (62.1) |
| ≥2 | 25 (37.9) |
| TKI | |
| Gefitinib | 42 (63.6) |
| Erlotinib | 24 (36.4) |
| Line | |
| 1st- or 2nd-line | 36 (54.5) |
| 3rd-line or above | 30 (45.5) |
| Extrathoracic metastasis | 52 (78.8) |
| Brain | 15 (22.7) |
| Bone | 25 (37.9) |
| No. of extrathoracic metastasis sites | |
| 1 | 36 (54.5) |
| 2 | 10 (15.2) |
| ≥3 | 6 (9.1) |
| Tumor response | |
| Partial response | 8 (12.1) |
| Stable disease | 19 (28.8) |
| Progressive disease | 39 (59.1) |
Values are presented as median (range) or number (%).
EGFR: epidermal growth factor receptor; TKI: tyrosine kinase inhibitor; ECOG PS: Eastern Cooperative Oncology Group performance status.